“1nhaler secures £2.2 million to continue late-stage development”

Key points

• Scotland-based 1nhaler raises £2.2 million in follow-on funding.
• Funding led by Archangels with Scottish Enterprise and BBB Investments.
• Aim to bring 1nhaler Salbutamol to regulatory submission by late 2027.
• Project includes transfer to contract manufacturing and small clinical trial.
• Cardboard, single-dose DPI seeks to reduce cost, waste and improve accessibility.